← Back to dossier
Patient handout

Undifferentiated dyspnea (ED)

PRODUCTION

1. Your condition

This handout is for undifferentiated dyspnea (ed). Your care team identified this based on: acute dyspnea presenting to ed — undifferentiated trigger for the full workup (welch jama 2005).

Other reasons your team may use this plan: orthopnea / pnd / peripheral edema — cardiogenic dyspnea cluster (maisel nejm 2002 bnp; 2022 aha/acc/hfsa hf heidenreich); pleuritic dyspnea ± unilateral leg pain — pe suspicion (esc 2019 pe konstantinides); wheezing dyspnea — asthma / copd exacerbation (gina 2026; gold 2026).

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • natural marker of fluid overload (BNP) >400 OR natural marker of fluid overload (NT-proBNP) > age-adjusted cutoff (>450 if <50 y, >900 50-75, >1800 >75) + orthopnea/PND + pulmonary edema on CXR / B-lines on POCUS (Maisel 2002 PMID 12124404; Heidenreich 2022 PMID 35379503)
  • Suspected PE + sustained hypotension (SBP <90 ×≥15 min) OR cardiac arrest with PEA/pulseless rhythm OR RV strain on POCUS with positive D-dimer (ESC 2019 PE Konstantinides PMID 35379503)(life-threatening)
  • Known COPD + worsening dyspnea + increased sputum + pH <7.35 + PaCO2 >45 on ABG (GOLD 2026)
  • Known asthma + peak flow <50% personal best OR FEV1 <50% predicted + accessory muscle use + oxygen level (SpO₂) <92% RA + speaking in short phrases (GINA 2026)
  • Sudden pleuritic dyspnea + tracheal deviation + decreased breath sounds + hyperresonance + hemodynamic compromise — bedside diagnosis, do NOT delay for imaging (ATS/CHEST 2010)(life-threatening)
  • Bilateral infiltrates on CXR + PaO2/FiO2 ≤300 + non-cardiogenic edema (natural marker of fluid overload (BNP)/natural marker of fluid overload (NT-proBNP) not consistent with HF, or echo without congestion) — Berlin criteria (Ranieri JAMA 2012; ATS/ESICM 2023)(life-threatening)
  • Acute onset (minutes-hours) skin/mucosal involvement (urticaria, angioedema, flushing) + ≥1 of: respiratory compromise (stridor, wheeze, hypoxia) OR hypotension OR persistent GI symptoms after likely allergen exposure (WAO 2020; Sampson NIAID criteria)(life-threatening)
  • Dyspnea on exertion + pallor + tachycardia + Hb drop / melena / hematemesis (ACG 2021 UGIB)
  • Dyspnea with Kussmaul respirations + glucose >250 + anion gap >12 + ketones + bicarb <18 (ADA 2026)
  • Dyspnea on exertion + RV failure signs (JVD, peripheral edema, hepatomegaly) + echo RVSP >40 OR RV strain — group 1-5 PH (ESC/ERS 2022 PH guideline)

5. Follow-up

Discharge: PCP / specialty f/u 7 d; return precautions (worsening dyspnea, fever, chest pain, syncope, hemoptysis); inhaler technique; smoking cessation; vaccinate (flu, COVID, pneumococcal — ATS/IDSA 2019; 2025 ACIP)

6. Sources

Guideline: 2022 AHA/ACC/HFSA Heart Failure Guideline (Heidenreich) + ESC 2019 PE (Konstantinides) + ATS/IDSA 2019 CAP (Metlay) + GOLD 2026 COPD + GINA 2026 Asthma + ATS/CHEST 2010 Pneumothorax + WAO 2020 Anaphylaxis + ATS/ESICM 2023 ARDS + ADA 2026 DKA + ESC/ERS 2022 PH

  1. pubmed.ncbi.nlm.nih.gov/41959959
  2. pubmed.ncbi.nlm.nih.gov/41883762